Flexeril and Odefsey drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Flexeril (cyclobenzaprine hydrochloride) and Odefsey (emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate). Common drug interactions include anhedonia among females and anxiety among males.

The phase IV clinical study analyzes what interactions people have when they take Flexeril and Odefsey. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Flexeril?

Flexeril has active ingredients of cyclobenzaprine hydrochloride. It is often used in muscle spasms. eHealthMe is studying from 38,308 Flexeril users. Check the latest studies of Flexeril.

What is Odefsey?

Odefsey has active ingredients of emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate. It is often used in hiv infection. eHealthMe is studying from 4,605 Odefsey users. Check the latest studies of Odefsey.



On Jul, 21, 2026

16 people who take Flexeril and Odefsey together, and have interactions are studied.

Flexeril and Odefsey drug interactions.

What are the common drug interactions of Flexeril and Odefsey, by gender? *:

female:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Chronic kidney disease
  4. Depression
  5. Emotional distress
  6. Pain
  7. Pollakiuria (abnormally frequent passage of relatively small quantities or urine)
  8. Renal failure (kidney dysfunction)
  9. Renal impairment (severely reduced kidney function)
  10. Sleep disorder

male:

  1. Anxiety
  2. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  3. Chronic kidney disease
  4. Depression
  5. Disturbance in attention
  6. Dizziness
  7. Dysphemia (stammering or stuttering)
  8. Executive dysfunction
  9. Fatigue (feeling of tiredness)
  10. Hallucination (an experience involving the perception of something not present)

What are the common drug interactions of Flexeril and Odefsey, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Bone density decreased
  2. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  3. Anxiety
  4. Bone pain
  5. Emotional distress
  6. Foot fracture
  7. Hand fracture
  8. Osteopenia (a condition where bone mineral density is lower than normal)
  9. Pain
  10. Vitamin d deficiency

40-49:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Bone density decreased
  4. Depression
  5. Emotional distress
  6. Hand fracture
  7. Ligament rupture (tear in ligament)
  8. Neck pain
  9. Osteoarthritis (a joint disease caused by cartilage loss in a joint)
  10. Osteopenia (a condition where bone mineral density is lower than normal)

50-59:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Chronic kidney disease
  4. Emotional distress
  5. Foot fracture
  6. Nephropathy (damage to or disease of a kidney)
  7. Pain
  8. Renal failure (kidney dysfunction)
  9. Multiple fractures

60+:

  1. Abnormal dreams
  2. Anxiety
  3. Memory impairment
  4. Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
  5. Muscular weakness (muscle weakness)
  6. Nausea (feeling of having an urge to vomit)
  7. Visual impairment
  8. Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
  9. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  10. Blood creatinine increased

What are the existing conditions these people have? *

  1. Prostate Cancer: 3 people, 18.75%
  2. Pain: 1 person, 6.25%
  3. Nausea (feeling of having an urge to vomit): 1 person, 6.25%
  4. Lipodystrophy Acquired (a regional loss of subcutaneous adipose tissue which usually starts in the face, extends downward acquired): 1 person, 6.25%
  5. Inflammation: 1 person, 6.25%
  6. Hypersensitivity: 1 person, 6.25%
  7. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 6.25%
  8. Fungal Infection: 1 person, 6.25%
  9. Depression: 1 person, 6.25%
  10. Bacterial Infection: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Flexeril and Odefsey?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Flexeril and Odefsey:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Flexeril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Odefsey:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Flexeril and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Odefsey and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on cyclobenzaprine hydrochloride and emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate (the active ingredients of Flexeril and Odefsey, respectively), and Flexeril and Odefsey (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: